WADA Prohibited List peptide revisions

Effective date and cadence

The WADA Prohibited List 2026 entered into force January 1, 2026. The List is revised at least once a year, so status dates matter.S2S3

Where peptides sit

The primary peptide class is S2 — Peptide hormones, growth factors, related substances and mimetics, and further examples and clarifications were added for 2026 to help athletes and support staff identify prohibited substances.S2S3 S2 covers, among others, growth-hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin, CJC-1295), agents affecting myostatin (follistatin, ACE-031), GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), and IGF-1 and its analogues.S1 Separately, BPC-157 sits under S0 — Non-Approved Substances, for substances with no current approval by any government health authority.S4 Substances in both S0 and S2 are prohibited at all times, in- and out-of-competition.S1S4

2026 Monitoring Program

From January 1, 2026, WADA's Monitoring Program tracks markers of semaglutide and tirzepatide, in- and out-of-competition, to watch for possible misuse. Monitoring is surveillance and does not by itself make a substance prohibited.S2S3

Practical takeaway

Peptides marketed for "recovery" or "healing" are frequently prohibited under S0 or S2, and a Therapeutic Use Exemption is generally not available for non-approved substances such as BPC-157.S4